All-trans-retinoic Acid Promotes Iodine Uptake Via Up-regulating the Sodium Iodide Symporter in Medullary Thyroid Cancer Stem Cells

  • Tang, Min (Department of Radiation Medicine, The First Affiliated Hospital, Chongqing Medical University) ;
  • Hou, Yan-Li (Department of Radiation Medicine, The First Affiliated Hospital, Chongqing Medical University) ;
  • Kang, Qiang-Qiang (Department of Radiation Medicine, The First Affiliated Hospital, Chongqing Medical University) ;
  • Chen, Xing-Yue (Department of Radiation Medicine, The First Affiliated Hospital, Chongqing Medical University) ;
  • Duan, Li-Qun (Department of Radiation Medicine, The First Affiliated Hospital, Chongqing Medical University) ;
  • Shu, Jin (Department of Radiation Medicine, The First Affiliated Hospital, Chongqing Medical University) ;
  • Li, Shao-Lin (Department of Radiation Medicine, The First Affiliated Hospital, Chongqing Medical University) ;
  • Hu, Xiao-Li (Department of Nuclear Medical, The First Affiliated Hospital, Chongqing Medical University) ;
  • Peng, Zhi-Ping (Department of Radiation Medicine, The First Affiliated Hospital, Chongqing Medical University)
  • Published : 2014.02.28


Recently, the main therapy of medullary thyroid cancer (MTC) is surgical, but by which way there is a poor prognosis with a mean survival of only 5 years. In some cases, some researchers found that it is the medullary thyroid cancer stem cells (MTCSCs) that cause metastasis and recurrence. This study aimed to eradicate MTCSCs through administration of all-trans-retinoic acid (ATRA). Here we demonstrate that MTCSCs possess stemlike properties in serum-free medium. The ABCG2, OCT4 and sodium iodide symporter (NIS) were changed by ATRA. Additionally, we found that ATRA can increase the expression of NIS in vivo. All the data suggested that ATRA could increase the iodine uptake of MTCSCs through NIS.


  1. Martin LP, Hamilton TC, Schilder RJ (2008). Platinum resistance: the role of DNA repair pathways. Clin Cancer Res, 14, 1291-5.
  2. Jordan CT, Guzman ML, Noble M (2006). Cancer stem cells. N Engl J Med, 355, 1253-61.
  3. Lin RY (2011). Thyroid cancer stem cells. Nat Rev Endocrinol, 7, 609-16.
  4. Lobo NA, Shimono Y, Qian D, et al (2007). The biology of cancer stem cells. Annu Rev Dev Bio, 23, 675-99.
  5. Rashidi A, Goudar RK, Sayedian F, et al (2013). All-trans retinoic acid and early mortality in acute promyelocytic leukemia. Leuk Res, 37, 1391-2.
  6. Reya T, Morrison SJ, Clarke MF, et al (2001). Weissman IL. Stem cells and cancer stem cells. Nature, 414, 105-11.
  7. Ryan J, Curran CE, Hennessy E, et al (2011). The sodium iodide symporter (NIS) and potential regulators in normal, benign and malignant human breast tissue. PLoS One, 6, e16023.
  8. Schmutzler C, Winzer R, Meissner-Weigl J, et al (1997). Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun, 240, 832-8.
  9. Segalla S, Rinaldi L, Kilstrup-Nielsen C, et al (2003). Retinoic acid receptor alpha fusion to PML affects its transcriptional and chromatin-remodeling properties. Mol Cell Biol, 23, 8795-808.
  10. Tabarestani S, Ghafouri-Fard S (2012). Cancer stem cells and response to therapy. Asian Pac J Cancer Prev, 13, 5947-54.
  11. Takahashi K, Yamanaka S (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126, 663-76.
  12. Doha'n O, Carrasco N (2003). Advances in Na (+)/I (-) symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol, 213, 59-70.
  13. Collins SJ (2002). The role of retinoids and retinoic acid receptors in normal hematopoiesis. Leukemia, 16, 1896-905.
  14. Cunha De Santis G, Tamarozzi MB, Sousa RB, et al (2007). Adhesion molecules and differentiation syndrome: phenotypic and functional analysis of the effect of ATRA, $As_{2}O_{3}$, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. Haematologica, 92, 1615-22.
  15. Damle N, Patnecha M, Kumar P, et al (2011). Retinoic acid therapy in patients with radioiodine negative differentiated thyroid cancer and clinical or biochemical evidence of disease: An initial experience. Indian J Nucl Med, 26, 144-8.
  16. Doha'n O, De la Vieja A, Paroder V, et al (2003). The sodium/ iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev, 24, 48-77.
  17. Elola M, Yoldi A, Emparanza JI, et al (2011). Redifferentiation therapy with rosiglitazone in a case of differentiated thyroid cancer with pulmonary metastases and absence of radioiodine uptake. Rev Esp Med Nucl, 30, 241-3.
  18. Foujilas C, Marakaki C, Sirmos N (2009). Sodium-iodine symporter in thyroid, normal and cancer tissues and its relation to nuclear medicine and to gene cloning treatment. Hell J Nucl Med, 12, 189-93.
  19. Francipane MG, Chandler J, Lagasse E (2013). Cancer stem cells: a moving target. Curr Pathobiol Rep, 1, 111-8.
  20. Hadnagy A, Gaboury L, Beaulieu R, Balicki D (2006). SP analysis may be used to identify cancer stem cell populations. Exp Cell Res, 312, 3701-10.
  21. Jiang W, Peng J, Zhang Y, et al (2012). The implications of cancer stem cells for cancer therapy. Int J Mol Sci, 13, 16636-57.
  22. Biermann K, Biersack HJ, Sabet A, et al (2011). Alternative therapeutic approaches in the treatment of primary and secondary dedifferentiated and medullarythyroid carcinoma. Semin Nucl Med, 41, 139-48.
  23. Ailles LE, Weissman IL (2007). Cancer stem cell in solid tumor. Curr Opin Biotechnol, 18, 460-6.
  24. Bao S, Wu Q, McLendon RE, et al (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444, 756-60.
  25. Baumann M, Krause M, Hill R (2008). Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer, 8, 545-54.
  26. Christina Zechel (2005). Requirement of retinoic acid receptor isotypes alpha, beta and gamma during the initial steps of neural differentiation of PCC7 cells. Mol Endocrinol, 19, 1629-45.
  27. Zhang AM, Fan Y, Yao Q, et al (2012).Identification of a cancer stem-like population in the Lewis lung cancer cell line. Asian Pacific J Cancer Prev, 13, 761-6.
  28. Tomita A, Kiyoi H, Naoe T (2013). Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. In J Hematol, 97, 717-25.
  29. Tseng LM, Huang PI, Chen YR, et al (2012). Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells. J Pharmacol Exp Ther, 341, 410-23.
  30. Weiss SJ, Philp NJ, Grollman EF (1984). Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology, 114, 1090-8.
  31. Yu J, Vodyanik MA, Smuga-Otto K, et al (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318, 1917-20.

Cited by

  1. A Novel All-trans Retinoid Acid Derivative N-(3-trifluoromethyl-phenyl)-Retinamide Inhibits Lung Adenocarcinoma A549 Cell Migration through Down-regulating Expression of Myosin Light Chain Kinase vol.15, pp.18, 2014,
  2. Experimental Study on Residual Tumor Angiogenesis after Cryoablation vol.15, pp.6, 2014,
  3. Family of microRNA-146 Regulates RARβ in Papillary Thyroid Carcinoma vol.11, pp.3, 2016,
  4. All-trans retinoic acid suppresses malignant characteristics of CD133-positive thyroid cancer stem cells and induces apoptosis vol.12, pp.8, 2017,